id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2185-0007,FDA,FDA-2022-E-2185,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-01-13T05:00:00Z,2025,1,2025-01-13T05:00:00Z,,2025-01-13T20:08:29Z,,0,0,09000064868b7e65
FDA-2022-E-2185-0006,FDA,FDA-2022-E-2185,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-01-18T05:00:00Z,2024,1,2024-01-18T05:00:00Z,,2025-01-13T19:51:37Z,,0,0,09000064863a977a
FDA-2022-E-2185-0005,FDA,FDA-2022-E-2185,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-11T05:00:00Z,2024,1,2024-01-11T05:00:00Z,,2024-01-11T20:55:22Z,,0,0,090000648638a3c3
FDA-2022-E-2185-0004,FDA,FDA-2022-E-2185,Determination of Regulatory Review Period for Purposes of Patent Extension; Nextstellis,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T14:56:17Z,2023-26988,0,0,090000648631666f
FDA-2022-E-2185-0003,FDA,FDA-2022-E-2185,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2022-09-21T04:00:00Z,2022,9,2022-09-21T04:00:00Z,,2022-09-21T19:30:55Z,,0,0,09000064853481dd
FDA-2022-E-2185-0002,FDA,FDA-2022-E-2185,"Patent Term Extension Application for  NEXTSTELLIS ® (drospirenone and estetrol tablets).U.S. Patent No. 7,732,43",Other,Application,2022-09-09T04:00:00Z,2022,9,2022-09-09T04:00:00Z,,2023-06-20T17:27:52Z,,0,0,09000064852dc87b
FDA-2022-E-2185-0001,FDA,FDA-2022-E-2185,Letter from U S Patent and Trademark Office,Other,Letter(s),2022-09-09T04:00:00Z,2022,9,2022-09-09T04:00:00Z,,2023-06-20T17:29:46Z,,0,0,09000064852dc5ff